Market Closed - Nasdaq 04:00:00 2024-04-17 pm EDT 5-day change 1st Jan Change
0.4714 USD -3.40% Intraday chart for BioVie Inc. +1.12% -62.59%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
BioVie Inc. Announces Pipeline Update and Near-Term Clinical Priorities CI
Top Midday Decliners MT
BioVie Prices $21 Million Offering of Shares, Warrants; Stock Slumps MT
North American Morning Briefing : Stock Futures Hover At Start of Busy Week DJ
BioVie Prices $21 Million Public Offering of Common Stock, Warrants MT
Sector Update: Health Care Stocks Rising Late Afternoon MT
Top Midday Gainers MT
Sector Update: Health Care Stocks Advance Friday Afternoon MT
BioVie Shares Rise as Alzheimer's, Parkinson's Drug Trials Show Potential Improvements MT
BioVie Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
Oppenheimer Adjusts BioVie Price Target to $5 From $12, Maintains Outperform Rating MT
BioVie Says Modified Phase 3 Trial for Alzheimer's Disease Treatment Missed Statistical Significance Amid Protocol Errors MT
BioVie Inc. Announces Efficacy Data from Phase 3 Trial of NE3107 in Patients with Mild to Moderate Alzheimer?s Disease CI
BioVie Reports 'Positive' Phase 2b Trial Data of BIV201 in Refractory Ascites MT
BioVie Inc. Presents Positive Clinical Safety Data from Phase 2b Trial of BIV201 in Refractory Ascites at the American Association for the Study of Liver Disease - The Liver Meeting® 2023 CI
BioVie Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023 CI
BioVie Announces Late-Breaking Abstract Presenting Clinical Safety Data from the Company's Ascites Phase 2 Trial Accepted for Presentation at AASLD - The Liver Meeting®? 2023 CI
North American Morning Briefing : Stock Futures Hit by Israel-Hamas Conflict; Oil Jumps DJ
North American Morning Briefing : Stock Futures, -2- DJ
BioVie Shares Rise After Completion of Last Patient Treatment Visit in Trial for Mild to Moderate Alzheimer's Disease MT
North American Morning Briefing : Stock Futures -2- DJ
BioVie Inc. Presents Data for NE3107 At 2023 International Congress of Parkinson?s Disease and Movement Disorders CI
BioVie Inc. Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Biovie Inc. Announces Phase 3 Trial of Ne3107 in Alzheimer's Disease CI
BioVie Inc. to Present Data Showing How NE3107 Potentially Regulates DNA Methylation of Specific Genes in a Manner Highly Correlated to Observed Improvements in Cognition and Biomarkers of Disease CI
Chart BioVie Inc.
More charts
BioVie Inc. is a clinical-stage company engaged in developing drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company’s drug candidate NE3107 inhibits inflammatory activation of extracellular single-regulated kinase (ERK) and nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions. In liver disease, its orphan drug candidate BIV201 (continuous infusion terlipressin) is for the treatment of refractory ascites due to liver cirrhosis. BIV201 is administered as a liquid formulation. The Company is also engaged in developing NE3107, an extracellular single-regulated kinase (ERK) inhibitor that selectively reduces neuroinflammation and insulin resistance. NE3107 is an orally administered small molecule to inhibit inflammation-driven insulin resistance and pathological inflammatory cascades.
Related indices
More about the company
Mean consensus
Number of Analysts
Last Close Price
Average target price